EMA Advises Against Use of Ivermectin for COVID-19 Outside of Clinical Trials

March 24, 2021
Pharmaceutical Technology Editors

The agency says that data do not support the use of ivermectin to prevent or treat COVID-19 outside of clinical trials.

The European Medicines Agency (EMA) announced on March 23, 2021 that use of ivermectin to prevent or treat COVID-19 outside of well-designed clinical trials is not supported by the data. EMA conducted a review of published laboratory studies, observational studies, clinical trials, and meta-analyses for ivermectin and found that current evidence was not sufficient to support the use of the drug outside clinical trials. According to the agency, laboratory studies showed that the drug could block SARS-CoV-2 replication but at higher concentrations than the currently authorized dose, and higher doses might increase side effects.

According to the agency, ivermectin is used to treat parasitic worm infestations and skin conditions such as rosacea. It is not authorized for use to prevent or treat COVID-19 in the European Union.

Source: EMA